Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Genetically engineered rat models for breast cancer.

Smits BM, Cotroneo MS, Haag JD, Gould MN.

Breast Dis. 2007;28:53-61. Review.

PMID:
18057543
2.

Special considerations in mouse models of breast cancer.

Borowsky A.

Breast Dis. 2007;28:29-38. Review. No abstract available.

PMID:
18057541
3.

Gpx2 is an overexpressed gene in rat breast cancers induced by three different chemical carcinogens.

Naiki-Ito A, Asamoto M, Hokaiwado N, Takahashi S, Yamashita H, Tsuda H, Ogawa K, Shirai T.

Cancer Res. 2007 Dec 1;67(23):11353-8.

4.
5.
6.

Characterizing a rat Brca2 knockout model.

Cotroneo MS, Haag JD, Zan Y, Lopez CC, Thuwajit P, Petukhova GV, Camerini-Otero RD, Gendron-Fitzpatrick A, Griep AE, Murphy CJ, Dubielzig RR, Gould MN.

Oncogene. 2007 Mar 8;26(11):1626-35. Epub 2006 Sep 11.

PMID:
16964288
7.

Studying drug resistance using genetically engineered mouse models for breast cancer.

Rottenberg S, Pajic M, Jonkers J.

Methods Mol Biol. 2010;596:33-45. doi: 10.1007/978-1-60761-416-6_3.

PMID:
19949919
8.

Recent advances in breast cancer biology.

Schultz LB, Weber BL.

Curr Opin Oncol. 1999 Nov;11(6):429-34. Review.

PMID:
10550005
9.

Mammary tumor development in dogs is associated with BRCA1 and BRCA2.

Rivera P, Melin M, Biagi T, Fall T, Häggström J, Lindblad-Toh K, von Euler H.

Cancer Res. 2009 Nov 15;69(22):8770-4. doi: 10.1158/0008-5472.CAN-09-1725. Epub 2009 Nov 3.

10.

Progestins and breast cancer.

Aupperlee M, Kariagina A, Osuch J, Haslam SZ.

Breast Dis. 2005-2006;24:37-57. Review.

PMID:
16917138
11.

The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J.

Clin Cancer Res. 2008 May 1;14(9):2861-9. doi: 10.1158/1078-0432.CCR-07-4436.

12.

The role of ras gene expression and transforming growth factor alpha production in the etiology and progression of rodent and human breast cancer.

Salomon DS, Ciardiello F, Valverius EM, Kim N.

Cancer Treat Res. 1991;53:107-57. Review. No abstract available.

PMID:
1672074
13.

Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.

Aaltonen K, Blomqvist C, Amini RM, Eerola H, Aittomäki K, Heikkilä P, Nevanlinna H.

Clin Cancer Res. 2008 Apr 1;14(7):1976-83. doi: 10.1158/1078-0432.CCR-07-4100.

14.

SIRTing through breast cancer is just a survivin' game.

Luo J, Altieri DC.

Mol Cell. 2008 Oct 24;32(2):159-60. doi: 10.1016/j.molcel.2008.10.007.

15.

Chromosome alterations in rat mammary tumor progression.

Aldaz CM, Gollahon LS, Chen A.

Prog Clin Biol Res. 1992;376:137-53. Review. No abstract available.

PMID:
1528918
16.

Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.

Melchor L, Honrado E, Huang J, Alvarez S, Naylor TL, García MJ, Osorio A, Blesa D, Stratton MR, Weber BL, Cigudosa JC, Rahman N, Nathanson KL, Benítez J.

Clin Cancer Res. 2007 Dec 15;13(24):7305-13.

17.

Absence of Ras mutations in rat DMBA-induced mammary tumors.

Samuelson E, Nilsson J, Walentinsson A, Szpirer C, Behboudi A.

Mol Carcinog. 2009 Feb;48(2):150-5. doi: 10.1002/mc.20464.

PMID:
18649354
18.

Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.

Walker LC, Waddell N, Ten Haaf A; kConFab Investigators, Grimmond S, Spurdle AB.

Breast Cancer Res Treat. 2008 Nov;112(2):229-36. Epub 2007 Dec 20.

PMID:
18095154
19.

Are all cancer genes equal?

Bartek J, Lukas J.

Nature. 2001 Jun 28;411(6841):1001-2. No abstract available.

PMID:
11429580
20.

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group.

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.

PMID:
18957670

Supplemental Content

Support Center